KIRSCH ARTHUR S 4
4 · Evommune, Inc. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
Evommune (EVMN) Director Arthur S. Kirsch Buys 10,000 Shares
What Happened
- Arthur S. Kirsch, a director of Evommune, bought 10,000 shares in open-market purchases on July 7, 2026. The reported weighted-average price was $13.30 per share, for an aggregate cost of approximately $133,000. This was a purchase (acquisition) rather than a sale.
Key Details
- Transaction date: 2026-07-07; filing date: 2026-07-08 (filed the next day — timely).
- Reported price: weighted average $13.30; actual trades ranged from $13.25 to $13.35 (per footnote).
- Total shares acquired: 10,000; total reported value: ~$133,000.
- Shares owned after transaction: not disclosed in the provided filing.
- Transaction code: P (purchase); securities held by a family trust (Kirsch is trustee) and Kirsch disclaims beneficial ownership except for his proportionate pecuniary interest (footnote).
- No 10b5-1 plan, option exercise, or award noted in this filing.
Context
- Open-market purchases by directors are often watched by investors as a direct personal investment signal, though filings alone don’t explain motivation. The shares here were placed into a family trust, which may affect how beneficial ownership is reported.
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
KIRSCH ARTHUR S
Director
Transactions
- Purchase
Common Stock
[F1][F2]2026-07-07$13.30/sh+10,000$133,000→ 10,000 total(indirect: By Trust)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Signature
/s/ Gregory S. Moss, Attorney-in-Fact|2026-07-08